EAR, NOSE and OROPHARYNX Updated: October 2020
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
List of New Drugs Approved in India from 1991 to 2000
LIST OF NEW DRUGS APPROVED IN INDIA FROM 1991 TO 2000 S. No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ciprofloxacin 0.3% w/v Eye Indicated in the treatment of February-1991 Drops/Eye Ointment/Ear Drop external ocular infection of the eye. 2 Diclofenac Sodium 1gm Gel March-1991 3 i)Cefaclor Monohydrate Antibiotic- In respiratory April-1991 250mg/500mg Capsule. infections, ENT infection, UT ii)Cefaclor Monohydrate infections, Skin and skin 125mg/5ml & 250mg/5ml structure infections. Suspension. iii)Cefaclor Monohydrate 100mg/ml Drops. iv)Cefaclor 187mg/5ml Suspension (For paediatric use). 4 Sheep Pox Vaccine (For April-1991 Veterinary) 5 Omeprazole 10mg/20mg Short term treatment of April-1991 Enteric Coated Granules duodenal ulcer, gastric ulcer, Capsule reflux oesophagitis, management of Zollinger- Ellison syndrome. 6 i)Nefopam Hydrochloride Non narcotic analgesic- Acute April-1991 30mg Tablet. and chronic pain, including ii)Nefopam Hydrochloride post-operative pain, dental 20mg/ml Injection. pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 7 Buparvaquone 5% w/v Indicated in the treatment of April-1991 Solution for Injection (For bovine theileriosis. Veterinary) 8 i)Kitotifen Fumerate 1mg Anti asthmatic drug- Indicated May-1991 Tablet in prophylactic treatment of ii)Kitotifen Fumerate Syrup bronchial asthma, symptomatic iii)Ketotifen Fumerate Nasal improvement of allergic Drops conditions including rhinitis and conjunctivitis. 9 i)Pefloxacin Mesylate Antibacterial- In the treatment May-1991 Dihydrate 400mg Film Coated of severe infection in adults Tablet caused by sensitive ii)Pefloxacin Mesylate microorganism (gram -ve Dihydrate 400mg/5ml Injection pathogens and staphylococci). iii)Pefloxacin Mesylate Dihydrate 400mg I.V Bottles of 100ml/200ml 10 Ofloxacin 100mg/50ml & Indicated in RTI, UTI, May-1991 200mg/100ml vial Infusion gynaecological infection, skin/soft lesion infection. -
Fixed Drug Eruption Due to a Cerumenolytic Ear Drop; Hydrogen Peroxide and Boric Acid: a Case Report
ISSN: 2688-8238 DOI: 10.33552/OJOR.2020.04.000577 Online Journal of Otolaryngology and Rhinology Case Report Copyright © All rights are reserved by Akif İşlek Fixed Drug Eruption Due to A Cerumenolytic Ear Drop; Hydrogen Peroxide and Boric Acid: A Case Report Akif İşlek1* and Engin Karaaslan2 1Nusaybin State Hospital, Otolaryngology-Head & Neck Surgery Clinic, Mardin, Turkey 2Nusaybin State Hospital, Dermatology and Venereology, Mardin, Turkey *Corresponding author: Received Date: October 24, 2020 Published Date: November 03, 2020 Akif İşlek, Nusaybin State Hospital, Otolaryngology-Head & Neck Surgery Clinic, Mardin, Turkey. Abstract Treatment of earwax often involves the use of a wax softening agent (cerumenolytic) with or without antimicrobial agents to easily removing. Cerumenolytic agents used to remove and soften earwax areoil-based treatments, water-based treatments. Fixed drug eruption (FDE) is a well- defined, circular, hyperpigmented plaque that usually occurs on the trunk, hands mucosal surfaces, after a systemical application of drugs. In this report, a case with FDE developed after a cerumenolytic agent (hydrogen peroxide and boric acid in water). A definitive diagnosis was made with skin punch biopsy and FDE was treated with oral levocetirizine and topical mometasone. Introduction is a well-defined, circular, hyper pigmenting plaque that usually Cerumen production is a normal and protective process occurs on the genitals, lips, trunk, and hands and the diagnosis for the external ear canal (EAC), but impact of cerumen causes can be confirmed by histopathologic examination of a small punch symptoms such as hearing loss, itching, pain, tinnitus [1]. Cerumen biopsy specimen [5]. In this report, a case with FDE developed after impaction is defined as an accumulation of cerumen in the a cerumenolytic agent (hydrogen peroxide and boric acid in water) external ear [2]. -
Antiseptics and Disinfectants for the Treatment Of
Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole. -
Identification of Candidate Agents Active Against N. Ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N
RESEARCH ARTICLE Identification of Candidate Agents Active against N. ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N. ceranae Infected Cultured Cells Sebastian Gisder, Elke Genersch* Institute for Bee Research, Department of Molecular Microbiology and Bee Diseases, Hohen Neuendorf, Germany * [email protected] Abstract OPEN ACCESS Many flowering plants in both natural ecosytems and agriculture are dependent on insect Citation: Gisder S, Genersch E (2015) Identification of Candidate Agents Active against N. ceranae pollination for fruit set and seed production. Managed honey bees (Apis mellifera) and wild Infection in Honey Bees: Establishment of a Medium bees are key pollinators providing this indispensable eco- and agrosystem service. Like all Throughput Screening Assay Based on N. ceranae other organisms, bees are attacked by numerous pathogens and parasites. Nosema apis is Infected Cultured Cells. PLoS ONE 10(2): e0117200. a honey bee pathogenic microsporidium which is widely distributed in honey bee popula- doi:10.1371/journal.pone.0117200 tions without causing much harm. Its congener Nosema ceranae was originally described Academic Editor: Wolfgang Blenau, Goethe as pathogen of the Eastern honey bee (Apis cerana) but jumped host from A. cerana to A. University Frankfurt, GERMANY mellifera about 20 years ago and spilled over from A. mellifera to Bombus spp. quite recent- Received: October 8, 2014 ly. N. ceranae is now considered a deadly emerging parasite of both Western honey bees Accepted: December 20, 2014 and bumblebees. Hence, novel and sustainable treatment strategies against N. ceranae are Published: February 6, 2015 urgently needed to protect honey and wild bees. -
(CD-P-PH/PHO) Report Classification/Justifica
COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82 -
4. Antibacterial/Steroid Combination Therapy in Infected Eczema
Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week. -
(CD-P-PH/PHO) Report Classification/Justifica
COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities. -
O SIEMSGLUSS IBERICA, S.A
SIEMSGLUSS IBERICA, S.A. Product list G Memantine HCI Propylparaben Sodium Pharma APls Gemfibrozil Mepiramina Maleato R Gentian Powder Methoxsalen Ramipril Gentian Violet Methyl Nicotinate Ranitidin HCI Glibenclamide Methylprednisolone Base Rapamycin (Slrollrnus) Glimepiride Metimazole Resorcin A e Gluthatione reduced Metronidazol Resveratrol (Veri-Te®) 11 Alpha Hydroxyprogesterone Caffein Anhydrous Cyproterone Acetate Guaiacol Glyceril Ether Mexiletine HcI Rifampicin 17 Alpha Estradiol Calcipotriol Mieonazole Nitrate o H Roxythromycin Acetyl Salicylic Acid Canrenone Miltefosine Desonide Micronized Hydroquinone AcetylSpiramycin Cantharidin Minocycline HcI Dexamethasone BaseMicro Hyaluronic Acid Sodium Salt s Adapalene Captopril Minoxidil Seenidazol Dexamethasone Isonicotinate Miero Hydrochlorthiazide Amidopyrine Carbamazepine Mometasone Furoato Silver Sulfadiazine Dexamethasone Sodium Phosphate Hydrocortisone Acetate Micro Amikacin Sulphate Carbidopa Montelukast Sodium Simvastatine Dexketoprofen Trometamol Hydrocortisone BaseMicro Amiloride Carisoprodol Sodium Cefonicide Dextrometorphan Bromhidrate Hydroxyzine HcI N Amitriptyline HCI Carvedilol $pironolactone Micro Dextrose (Glucosa) Anhydrous N Aeetyl Glueosamine Amoxlcillin Na + Clavulonate K Cefaclor Monohidrate Sulpiride Diacethyl Naproxen Powder Ibuprofen Amoxicillin Na + Clavulonate K(5:1) Cefadroxil Compaeted Dielofenae Sodium Neutral Pellets Idebenone T Amoxicillin Trihydrate Compacted Cefalexine Monohydrate Powder Difenhydramire Nisin Taerollmus Monohydrate Imiquimod Amoxlcillln -
Clioquinol: Summary Report
Clioquinol: Summary Report Item Type Report Authors Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Yuen, Melissa V.; Mattingly, Ashlee N. Publication Date 2020-01 Keywords Clioquinol; Compounding; Food, Drug, and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Drug compounding; Legislation, Drug; United States Food and Drug Administration Rights Attribution-NoDerivatives 4.0 International Download date 24/09/2021 22:12:31 Item License http://creativecommons.org/licenses/by-nd/4.0/ Link to Item http://hdl.handle.net/10713/12091 Summary Report Clioquinol Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy January 2020 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATIONS ................................................................................................... 4 METHODOLOGY ................................................................................................................... -
Effect of 8-Hydroxyquinoline and Derivatives on Human Neuroblastoma SH-SY5Y Cells Under High Glucose
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Effect of 8-hydroxyquinoline and derivatives on human neuroblastoma SH-SY5Y cells under high glucose Wilasinee Suwanjang1, Supaluk Prachayasittikul2 and Virapong Prachayasittikul3 1 Center for Research and Innovation, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand 2 Center of Data Mining and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand 3 Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand ABSTRACT 8-Hydroxyquinoline and derivatives exhibit multifunctional properties, including antioxidant, antineurodegenerative, anticancer, anti-inflammatory and antidiabetic activities. In biological systems, elevation of intracellular calcium can cause calpain activation, leading to cell death. Here, the effect of 8-hydroxyquinoline and derivatives (5-chloro-7-iodo-8-hydroxyquinoline or clioquinol and 8-hydroxy-5-nitroquinoline or nitroxoline) on calpain-dependent (calpain-calpastatin) pathways in human neu- roblastoma (SH-SY5Y) cells was investigated. 8-Hydroxyquinoline and derivatives ameliorated high glucose toxicity in SH-SY5Y cells. The investigated compounds, particularly clioquinol, attenuated the increased expression of calpain, even under high- glucose conditions. 8-Hydroxyquinoline and derivatives thus adversely affected the promotion of neuronal cell death by high glucose via the calpain-calpastatin -
Updates in Pediatric Dermatology
Peds Derm Updates ELIZABETH ( LISA) SWANSON , M D ADVANCED DERMATOLOGY COLORADO ROCKY MOUNTAIN HOSPITAL FOR CHILDREN [email protected] Disclosures Speaker Sanofi Regeneron Amgen Almirall Pfizer Advisory Board Janssen Powerpoints are the peacocks of the business world; all show, no meat. — Dwight Schrute, The Office What’s New In Atopic Dermatitis? Impact of Atopic Dermatitis Eczema causes stress, sleeplessness, discomfort and worry for the entire family Treating one patient with eczema is an example of “trickle down” healthcare Patients with eczema have increased risk of: ADHD Anxiety and Depression Suicidal Ideation Parental depression Osteoporosis and osteopenia (due to steroids, decreased exercise, and chronic inflammation) Impact of Atopic Dermatitis Sleep disturbances are a really big deal Parents of kids with atopic dermatitis lose an average of 1-1.5 hours of sleep a night Even when they sleep, kids with atopic dermatitis don’t get good sleep Don’t enter REM as much or as long Growth hormone is secreted in REM (JAAD Feb 2018) Atopic Dermatitis and Food Allergies Growing evidence that food allergies might actually be caused by atopic dermatitis Impaired barrier allows food proteins to abnormally enter the body and stimulate allergy Avoiding foods can be harmful Proper nutrition is important Avoidance now linked to increased risk for allergy and anaphylaxis Refer severe eczema patients to Allergist before 4-6 mos of age to talk about food introduction Pathogenesis of Atopic Dermatitis Skin barrier -
RIEMSER Group International Product List
RIEMSER Group International Product List Product Active substance Presentation Indication Product Category Channel EMB Fatol Ethambutol • POI 1g/10ml Treatment of several forms and stages of Anti-infectives Rx dihydrochloride • TAB 100mg tuberculosis • FCT 400, 500 mg Eremfat Rifampicin • GRA 1.2g/60ml Anti-infectives Rx • POI 300, 600mg Tuberculosis therapy , combination treatment of • FCT 150, 300, 450, 600 leprosy, prophylaxis for meningococcal meningitis, treatment of infections caused by nontuberculous mycobacteria Isozid Isoniazid • TAB 50, 100, 200 mg During Chemotherapy, -prophylaxis and - Anti-infectives Rx • POI 500mg prevention for / of tuberculosis Isozidcomp Isoniazid / pyridoxine • TAB 100mg / 20mg Chemotherapy, -prophylaxis and -prevention for / Anti-infectives Rx • FCT 200mg /40 mg, 300mg/60mg of Tuberculosis PAS-Fatol Sodium aminosalicylate • POI 13.49g Chemotherapy for tuberculosis, caused by Anti-infectives Rx dihydrate mycobacterium tuberculosis and mycobacterium bovis. Peteha Protionamide • FCT 250mg Treatment of tuberculosis, leprosy and diseases Anti-infectives Rx caused by so-called ubiquitours (atypical) mycobacteria Pyrafat Pyrazinamide • FCT 500mg Combination therapy for all types of tuberculosis, Anti-infectives Rx • TAB 500mg caused by mycobacterium tuberculosis, mycobacterium africanum, or mycobacterium microtti. Terizidon Terizidone • CAP 250mg Treatment of tuberculosis caused by Anti-infectives Rx mycobacterium tuberculosis Vancomycin Enterocaps Vancomycin • CAP 250 mg Treatment of certain types of bowel